UCB flashes the data behind its positive psoriasis readouts. Can it compete in a crowded field?
Eight months after UCB announced that a little-watched drug candidate outperformed J&J’s blockbuster Stelara, the Belgian pharma is out with full data that one investigator calls “remarkable.”
In the Phase III trial, 58.6% of patients who took UCB’s IL-17 blocker bimekizumab were completely cleared of skin lesions after 16 weeks, compared to 20.9% of patients on Stelara. The UCB drug also outperformed Stelara at how many patients were clear after one year and at lesser benchmarks for plaque clearance, with more than 8 out of 10 patients showing 90% improvement, compared to roughly half on Stelara.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
